Analyst Ratings for Regeneron Pharmaceuticals Inc. (REGN)

Updated: 2017-07-28

Analysts covering Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) have given it a consensus rating of Overweight. A consensus rating of Overweight was previously issued for REGN last month.

Of the 24 analysts covering the stock, 10 gave it a buy rating, 1 issued an overweight rating, 13 gave a hold rating, 0 gave an underweight rating, and 0 gave a sell rating. Compared to three months ago, there has been an decrease of 3 in the number of analysts with a positive outlook on the stock. Meanwhile, the number of analysts pessimistic about the company has increased by 0.

Many analysts weighed in on price targets for REGN. The maximum price target given was 593, implying potential capital gains of 16.64 percent. The lowest price target was 327, implying a possible loss of -35.68 percent. Note that investment analysts can be biased in their reporting on companies's ratings and price targets.

In the last 30 days, analysts have changed their quarterly earnings estimates upwards by an average of 0.48 percent. This can be compared with the average change in earnings estimates over the past 3 months, which is -0.14 percent. Over the past 30 days, FY earnings estimates have also changed upwards by 0.39 percent. If we look at the last 90 days instead, we find a net average change of 0.77 percent in FY estimates.

Another thing investors often look at is the level of agreement among analysts' revisions. 1 analysts have revised their quarterly estimates upwards in the past 30 days, while 0 analysts made negative revisions. Also over the last month, 1 analysts increased their estimates for the FY earnings, while 0 analysts decreased their estimates.

The growth rate of REGN's earnings is estimated by analysts to be 24.83 percent. It's possible to gain additional insight about growth valuation of a company by looking at the PEG ratio. A lower PEG ratio is favorable, as that can indicate whether the high price level of a stock is warranted by high growth. Many investors consider PEG ratios between 0 and 1 as preferrable, even though it may be more relevant to compare the ratio to that of a firm's competitors. The PEG ratio of REGN is 2.46.

In the trailing 52-weeks, REGN hit 543.55 at the highest peak, while it's lowest trading point was 325.35. Currently the stock is 56.27 percent higher than its low, and 6.46 percent lower than its 52-week high. REGN has a P/E ratio of 61.18. Investors typically compare the P/E ratio to a company's peers in the industry. The REGN value stock report compares REGN to some of its peers using value stock charts. The market cap of REGN is $54.81 billion. REGN's next earnings release will be on 0000-00-00, which is days away.